Skip to Content
Merck
CN

581394-U

Discovery® HS C18 (10 µm) HPLC Columns

L × I.D. 1 cm × 21.2 mm HPLC Prep Guard Cartridge

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

UNSPSC Code:
41115700
eCl@ss:
32110501
NACRES:
SB.52
L × i.d.:
1 cm × 21.2 mm
Particle size:
10 μm
Matrix active group:
C18 (octadecyl) phase
Pore size:
120 Å
Matrix:
fully porous particle
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


Product Name

Discovery® HS C18 Prep Guard Cartridge, 10 μm particle size, L × I.D. 1 cm × 21.2 mm

material

stainless steel column

Quality Level

agency

suitable for USP L1

description

Prep Cartridge

product line

Discovery®

feature

endcapped

packaging

pkg of 1 ea

technique(s)

HPLC: suitable, LC/MS: suitable

L × I.D.

1 cm × 21.2 mm

surface area

300 m2/g

matrix

fully porous particle

matrix active group

C18 (octadecyl) phase

particle size

10 μm

pore size

120 Å

operating pH

2-8

application(s)

food and beverages

compatibility

use to protect Discovery HS C18 Prep

separation technique

reversed phase

Other Notes

Discover LiChropur reagents ideal for HPLC or LC-MS analysis

Legal Information

Discovery is a registered trademark of Merck KGaA, Darmstadt, Germany


Still not finding the right product?


Regulatory Information

新产品

This item has



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



Swati Jaiswal et al.
Journal of chromatographic science, 55(6), 617-624 (2017-03-24)
Tuberculosis (TB) with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome represents the most common infectious diseases worldwide. Anti-TB drugs are used concurrently with antiretroviral drug for treatment of TB-HIV co-morbidities. Due to lower risk of interaction with protease inhibitors, rifabutin is
Jolanta Flieger et al.
Journal of separation science, 34(7), 733-739 (2011-03-02)
Highly hydrophilic compounds belonging to biogenic amines were analysed in the reversed-phase system, modified with the addition of ionic liquids: 1-ethyl-3-methyl-imidazolium hexafluorophosphate (EMIM PF(6)) and chaotropic salt NaPF(6) on Discovery HS C18 column at acidic conditions. The effect of the
Abad Khan et al.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 878(28), 2782-2788 (2010-09-11)
A rapid, inexpensive, sensitive and specific HPLC-ECD method for the determination of lipoic acid in human plasma was developed and validated over the linearity range of 0.001-10μg/ml using naproxen sodium as an internal standard (IS). Extraction of lipoic acid and



Global Trade Item Number

SKUGTIN
581394-U04061833518700